REVENUE (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Total Revenue by Type and by U.S versus Rest of World

The following table presents detail regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”):

	Three months ended September 30,
	2023						2022
(in millions)	U.S.		RoW		Total		U.S.		RoW		Total
Testing revenues:
Hereditary Cancer	$	75.1	$	11.4	$	86.5	$	60.2	$	10.3	$	70.5
Tumor Profiling	22.0		8.2		30.2		20.2		10.6		30.8
Prenatal	39.4		0.1		39.5		21.9		0.2		22.1
Pharmacogenomics	35.7		—		35.7		33.0		—		33.0
Total revenue	$	172.2	$	19.7	$	191.9	$	135.3	$	21.1	$	156.4
	Nine months ended September 30,
	2023						2022
(in millions)	U.S.		RoW		Total		U.S.		RoW		Total
Testing revenues:
Hereditary Cancer	$	203.6	$	35.3	$	238.9	$	190.6	$	30.0	$	220.6
Tumor Profiling	78.1		25.4		103.5		61.4		35.5		96.9
Prenatal	110.8		0.5		111.3		86.7		0.6		87.3
Pharmacogenomics	102.9		—		102.9		95.5		—		95.5
Autoimmune	—		—		—		0.3		—		0.3
Total revenue	$	495.4	$	61.2	$	556.6	$	434.5	$	66.1	$	500.6